Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia:: A 12-week double-blind, placebo-controlled pilot study
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia:: A 12-week double-blind, placebo-controlled pilot study
复制标题
DOI：
10.1016/j.psychres.2008.01.011
复制
发表时间：
2008-05-30
影响因子：
11.3
通讯作者：
de Baptista, Enma Araujo
中科院分区：
文献类型：
--
作者：
Baptista, Trino;Uzcategui, Euderruh;de Baptista, Enma Araujo
奥氮平治疗的慢性精神分裂症患者给予二甲双胍(850~1700 mg)联合西布曲明(10~20 mg，n=13)或安慰剂(n=15)治疗12周。两组的体重减轻相似：-2.8+/-3.2公斤对-1.4+/-2.6公斤。除了防止甘油三酯增加外，这种药物组合在临床人群中缺乏代谢控制的效果。(C)2008爱思唯尔爱尔兰有限公司。保留所有权利。
Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients. Weight loss was similar in both groups: -2.8 +/- 3.2 kg vs. -1.4 +/- 2.6 kg. Except for preventing a triglyceride increase, the drug combination lacked efficacy for metabolic control in this clinical population. (C) 2008 Elsevier Ireland Ltd. All rights reserved.